ResearcherUC Davis Comprehensive Cancer CenterActive in the last 2 years

Suyakarn Archasappawat

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 7 November 2026

Matched on OpenAlex author ID A5052699073. Sources: OpenAlex.

Their work

Papers: 2 (first author 1, last author 0)
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 5

Papers, trials and grants by year

2023: 1 paper · 2024: 1 paper

Papers 2

Familial Pancreatic Cancer Research: Bridging Gaps in Basic Research and Clinical Application. Co-author DOI 10.3390/biom14111381 ↗
A new vulnerability to BET inhibition due to enhanced autophagy in BRCA2 deficient pancreatic cancer. First author DOI 10.1038/s41419-023-06145-9 ↗

Closest collaborators

The 5 strongest of 5 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Eunjung Lee · 2 shared papers, 2023–2024 · strength 0.44
- Paper Familial Pancreatic Cancer Research: Bridging Gaps in Basic Research and Clinical Application. DOI 10.3390/biom14111381 ↗
- Paper A new vulnerability to BET inhibition due to enhanced autophagy in BRCA2 deficient pancreatic cancer. DOI 10.1038/s41419-023-06145-9 ↗
Chang‐Il Hwang · 2 shared papers, 2023–2024 · strength 0.44
- Paper Familial Pancreatic Cancer Research: Bridging Gaps in Basic Research and Clinical Application. DOI 10.3390/biom14111381 ↗
- Paper A new vulnerability to BET inhibition due to enhanced autophagy in BRCA2 deficient pancreatic cancer. DOI 10.1038/s41419-023-06145-9 ↗
Peinan Liu · 1 shared paper, 2024 · strength 0.28
- Paper Familial Pancreatic Cancer Research: Bridging Gaps in Basic Research and Clinical Application. DOI 10.3390/biom14111381 ↗
Timothy Spicer · 1 shared paper, 2023 · strength 0.16
- Paper A new vulnerability to BET inhibition due to enhanced autophagy in BRCA2 deficient pancreatic cancer. DOI 10.1038/s41419-023-06145-9 ↗
Virneliz Fernández-Vega · 1 shared paper, 2023 · strength 0.16
- Paper A new vulnerability to BET inhibition due to enhanced autophagy in BRCA2 deficient pancreatic cancer. DOI 10.1038/s41419-023-06145-9 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.